Exagen (XGN) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

XGN Stock Forecast

Exagen stock forecast is as follows: an average price target of $5.00 (represents a 22.85% upside from XGN’s last price of $4.07) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

XGN Price Target

The average price target for Exagen (XGN) is $5.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $5.00. This represents a potential 22.85% upside from XGN's last price of $4.07.

XGN Analyst Ratings

Buy

According to 3 Wall Street analysts, Exagen's rating consensus is 'Buy'. The analyst rating breakdown for XGN stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Exagen Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 12, 2024	Mark Massaro	BTIG	$5.00	$2.79	79.21%	22.85%
May 14, 2024	Kyle Mikson	Canaccord Genuity	$5.00	$1.64	204.88%	22.85%
Nov 17, 2022		BTIG	$7.00	$3.40	105.88%	71.99%

The latest Exagen stock forecast, released on Nov 12, 2024 by Mark Massaro from BTIG, set a price target of $5.00, which represents a 79.21% increase from the stock price at the time of the forecast ($2.79), and a 22.85% increase from XGN last price ($4.07).

Exagen Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	2
Avg Price Target	-	$5.00	$5.00
Last Closing Price	$4.07	$4.07	$4.07
Upside/Downside	-100.00%	22.85%	22.85%

In the current month, the average price target of Exagen stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Exagen's last price of $4.07. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 12, 2024	BTIG	Buy	Buy	Hold
Nov 12, 2024	KeyBanc	Sector Weight	Sector Weight	Hold
May 14, 2024	Cantor Fitzgerald	Overweight	Overweight	Hold
Mar 22, 2023	BTIG	Buy	Buy	Hold

Exagen's last stock rating was published by BTIG on Nov 12, 2024. The company gave XGN a "Buy" rating, the same as its previous rate.

Exagen Financial Forecast

Exagen Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$13.77M	$13.42M	$14.14M	$11.23M	$12.84M	$14.73M	$8.96M	$10.39M	$12.69M	$12.25M	$12.77M	$10.59M	$12.67M	$10.78M	$8.95M	$9.58M	$10.21M	$10.44M
Avg Forecast	$18.60M	$17.40M	$19.50M	$16.60M	$18.42M	$16.78M	$16.68M	$14.92M	$13.85M	$13.57M	$13.13M	$13.09M	$11.56M	$10.33M	$10.93M	$9.41M	$8.66M	$9.04M	$12.03M	$10.00M	$11.71M	$12.13M	$11.48M	$10.45M	$10.69M	$8.72M	$4.67M	$7.73M	$10.43M	$9.02M
High Forecast	$19.09M	$17.86M	$20.01M	$17.04M	$18.90M	$17.22M	$17.12M	$15.31M	$14.21M	$13.57M	$13.13M	$13.09M	$11.83M	$10.33M	$11.22M	$9.65M	$8.78M	$9.04M	$12.03M	$10.00M	$11.71M	$12.13M	$11.48M	$10.45M	$10.69M	$8.72M	$4.67M	$7.73M	$10.43M	$9.02M
Low Forecast	$18.15M	$16.98M	$19.03M	$16.20M	$17.97M	$16.37M	$16.28M	$14.56M	$13.51M	$13.57M	$13.13M	$13.09M	$11.32M	$10.33M	$10.67M	$9.18M	$8.50M	$9.04M	$12.03M	$10.00M	$11.71M	$12.13M	$11.48M	$10.45M	$10.69M	$8.72M	$4.67M	$7.73M	$10.43M	$9.02M
# Analysts	1	1	1	1	1	1	1	3	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2	2	1	1
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.19%	1.30%	1.29%	1.19%	1.48%	1.63%	0.74%	1.04%	1.08%	1.01%	1.11%	1.01%	1.18%	1.23%	1.92%	1.24%	0.98%	1.16%

Exagen's average Quarter revenue forecast for Mar 24 based on 2 analysts is $13.09M, with a low forecast of $13.09M, and a high forecast of $13.09M. XGN's average Quarter revenue forecast represents a -4.93% decrease compared to the company's last Quarter revenue of $13.77M (Dec 23).

Exagen EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2	2	1	1
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-4.64M	$-5.07M	$-4.92M	$-6.50M	$-8.50M	$-7.48M	$-12.39M	$-9.39M	$-5.95M	$-6.25M	$-5.53M	$-5.38M	$-2.61M	$-3.52M	$-2.60M	$-4.92M	$-2.50M	$-2.12M
Avg Forecast	$-8.60M	$-8.04M	$-9.01M	$-7.67M	$-8.51M	$-7.75M	$-7.71M	$-6.90M	$-6.40M	$-6.27M	$-6.07M	$-6.05M	$-5.34M	$-4.77M	$-5.05M	$-4.35M	$-4.00M	$-4.19M	$-5.58M	$-9.00	$-5.43M	$-5.63M	$-5.32M	$-5.26M	$-4.96M	$-4.05M	$-2.16M	$-5.43M	$-4.84M	$-2.20M
High Forecast	$-8.39M	$-7.85M	$-8.79M	$-7.49M	$-8.31M	$-7.57M	$-7.52M	$-6.73M	$-6.25M	$-6.27M	$-6.07M	$-6.05M	$-5.23M	$-4.77M	$-4.93M	$-4.24M	$-3.93M	$-4.19M	$-5.58M	$-7.00	$-5.43M	$-5.63M	$-5.32M	$-4.21M	$-4.96M	$-4.05M	$-2.16M	$-4.34M	$-4.84M	$-1.76M
Low Forecast	$-8.82M	$-8.25M	$-9.25M	$-7.87M	$-8.74M	$-7.96M	$-7.91M	$-7.08M	$-6.57M	$-6.27M	$-6.07M	$-6.05M	$-5.47M	$-4.77M	$-5.18M	$-4.46M	$-4.06M	$-4.19M	$-5.58M	$-11.00	$-5.43M	$-5.63M	$-5.32M	$-6.32M	$-4.96M	$-4.05M	$-2.16M	$-6.51M	$-4.84M	$-2.64M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.87%	1.06%	0.97%	1.49%	2.12%	1.78%	2.22%	1043444.44%	1.10%	1.11%	1.04%	1.02%	0.53%	0.87%	1.20%	0.91%	0.52%	0.96%

undefined analysts predict XGN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Exagen's previous annual EBITDA (undefined) of $NaN.

Exagen Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2	2	1	1
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-5.57M	$-5.42M	$-5.01M	$-8.31M	$-14.35M	$-2.37M	$-13.91M	$-10.87M	$-7.05M	$-7.18M	$-6.41M	$-6.21M	$-3.45M	$-4.31M	$-3.36M	$-5.56M	$-3.41M	$-3.14M
Avg Forecast	$-1.10M	$-2.01M	$-730.20K	$-2.56M	$-2.01M	$-2.96M	$-3.10M	$-4.24M	$-4.75M	$-5.29M	$-6.21M	$-6.59M	$-7.86M	$-8.58M	$-9.05M	$-10.26M	$-14.00M	$-13.94M	$-10.34M	$-10.00	$-8.73M	$-8.36M	$-7.95M	$-6.08M	$-7.21M	$-8.59M	$-13.75M	$-6.13M	$-6.67M	$-3.27M
High Forecast	$-1.06M	$-1.94M	$-707.20K	$-2.48M	$-1.94M	$-2.86M	$-3.01M	$-4.10M	$-4.60M	$-5.12M	$-6.01M	$-6.38M	$-7.61M	$-8.31M	$-8.76M	$-9.93M	$-13.67M	$-13.94M	$-10.34M	$-8.00	$-8.73M	$-8.36M	$-7.95M	$-4.86M	$-7.21M	$-8.59M	$-13.75M	$-4.90M	$-6.67M	$-2.62M
Low Forecast	$-1.13M	$-2.08M	$-755.11K	$-2.64M	$-2.08M	$-3.06M	$-3.21M	$-4.38M	$-4.91M	$-5.47M	$-6.42M	$-6.81M	$-8.13M	$-8.87M	$-9.36M	$-10.61M	$-14.26M	$-13.94M	$-10.34M	$-12.00	$-8.73M	$-8.36M	$-7.95M	$-7.29M	$-7.21M	$-8.59M	$-13.75M	$-7.36M	$-6.67M	$-3.93M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.71%	0.63%	0.55%	0.81%	1.03%	0.17%	1.34%	1086500.00%	0.81%	0.86%	0.81%	1.02%	0.48%	0.50%	0.24%	0.91%	0.51%	0.96%

Exagen's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. XGN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Exagen SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2	2	1	1
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$12.22M	$11.38M	$11.95M	$11.88M	$12.81M	$14.15M	$12.90M	$12.15M	$11.80M	$11.53M	$11.17M	$10.04M	$9.93M	$9.20M	$8.28M	$9.63M	$7.92M	$7.31M
Avg Forecast	$16.96M	$15.87M	$17.78M	$15.14M	$16.80M	$15.30M	$15.21M	$13.61M	$12.63M	$12.38M	$11.97M	$11.93M	$10.54M	$9.42M	$9.97M	$8.58M	$7.90M	$8.25M	$10.97M	$11.00	$10.68M	$11.06M	$10.47M	$9.83M	$9.75M	$7.96M	$4.26M	$7.05M	$9.51M	$7.61M
High Forecast	$17.41M	$16.28M	$18.25M	$15.53M	$17.24M	$15.70M	$15.61M	$13.96M	$12.96M	$12.38M	$11.97M	$11.93M	$10.79M	$9.42M	$10.23M	$8.80M	$8.01M	$8.25M	$10.97M	$14.00	$10.68M	$11.06M	$10.47M	$11.79M	$9.75M	$7.96M	$4.26M	$7.05M	$9.51M	$9.13M
Low Forecast	$16.55M	$15.48M	$17.35M	$14.77M	$16.39M	$14.93M	$14.84M	$13.28M	$12.32M	$12.38M	$11.97M	$11.93M	$10.32M	$9.42M	$9.73M	$8.37M	$7.75M	$8.25M	$10.97M	$9.00	$10.68M	$11.06M	$10.47M	$7.86M	$9.75M	$7.96M	$4.26M	$7.05M	$9.51M	$6.09M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.16%	1.21%	1.20%	1.39%	1.62%	1.72%	1.18%	1104727.27%	1.11%	1.04%	1.07%	1.02%	1.02%	1.16%	1.94%	1.37%	0.83%	0.96%

Exagen's average Quarter SG&A projection for Mar 24 is $11.93M, based on 2 Wall Street analysts, with a range of $11.93M to $11.93M. The forecast indicates a -2.32% fall compared to XGN last annual SG&A of $12.22M (Dec 23).

Exagen EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2	2	1	1
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-0.31	$-0.00	$-0.00	$-0.47	$-0.84	$-0.14	$-0.82	$-0.64	$-0.42	$-0.42	$-0.38	$-0.48	$-0.27	$-0.34	$-0.27	$-0.44	$-0.27	$-11.29
Avg Forecast	$-0.06	$-0.11	$-0.04	$-0.14	$-0.11	$-0.16	$-0.17	$-0.23	$-0.26	$-0.29	$-0.34	$-0.36	$-0.43	$-0.47	$-0.50	$-0.56	$-0.77	$-0.77	$-0.57	$-0.61	$-0.48	$-0.46	$-0.44	$-0.47	$-0.40	$-0.47	$-0.76	$-0.49	$-0.37	$-0.58
High Forecast	$-0.06	$-0.11	$-0.04	$-0.14	$-0.11	$-0.16	$-0.16	$-0.22	$-0.25	$-0.28	$-0.33	$-0.35	$-0.42	$-0.46	$-0.48	$-0.54	$-0.75	$-0.77	$-0.57	$-0.61	$-0.48	$-0.46	$-0.44	$-0.47	$-0.40	$-0.47	$-0.76	$-0.49	$-0.37	$-0.58
Low Forecast	$-0.06	$-0.11	$-0.04	$-0.14	$-0.11	$-0.17	$-0.18	$-0.24	$-0.27	$-0.30	$-0.35	$-0.37	$-0.45	$-0.49	$-0.51	$-0.58	$-0.78	$-0.77	$-0.57	$-0.61	$-0.48	$-0.46	$-0.44	$-0.47	$-0.40	$-0.47	$-0.76	$-0.49	$-0.37	$-0.58
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.72%	0.00%	0.00%	0.84%	1.10%	0.18%	1.44%	1.05%	0.87%	0.91%	0.87%	1.02%	0.68%	0.72%	0.36%	0.90%	0.74%	19.47%

According to undefined Wall Street analysts, Exagen's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to XGN previous annual EPS of $NaN (undefined).

Exagen Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
DRIO	DarioHealth	$0.66	$10.75	1528.79%	Buy
BDSX	Biodesix	$1.04	$3.00	188.46%	Buy
CSTL	Castle Biosciences	$27.49	$40.50	47.33%	Buy
XGN	Exagen	$4.07	$5.00	22.85%	Buy
SHC	Sotera Health	$13.68	$16.00	16.96%	Buy

XGN Forecast FAQ

Is Exagen a good buy?

Yes, according to 3 Wall Street analysts, Exagen (XGN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of XGN's total ratings.

What is XGN's price target?

Exagen (XGN) average price target is $5 with a range of $5 to $5, implying a 22.85% from its last price of $4.07. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Exagen stock go up soon?

According to Wall Street analysts' prediction for XGN stock, the company can go up by 22.85% (from the last price of $4.07 to the average price target of $5), up by 22.85% based on the highest stock price target, and up by 22.85% based on the lowest stock price target.

Can Exagen stock reach $6?

XGN's average twelve months analyst stock price target of $5 does not support the claim that Exagen can reach $6 in the near future.

What are Exagen's analysts' financial forecasts?

Exagen's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $66.8M (high $68.55M, low $65.18M), average EBITDA is $-30.871M (high $-30.124M, low $-31.682M), average net income is $-12.304M (high $-11.916M, low $-12.724M), average SG&A $60.91M (high $62.51M, low $59.44M), and average EPS is $-0.674 (high $-0.653, low $-0.697). XGN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $72.1M (high $73.99M, low $70.35M), average EBITDA is $-33.321M (high $-32.514M, low $-34.195M), average net income is $-6.389M (high $-6.188M, low $-6.607M), average SG&A $65.75M (high $67.47M, low $64.15M), and average EPS is $-0.35 (high $-0.339, low $-0.362).

Did the XGN's actual financial results beat the analysts' financial forecasts?

Based on Exagen's last annual report (Dec 2023), the company's revenue was $52.55M, beating the average analysts forecast of $42.22M by 24.45%. Apple's EBITDA was $-22.837M, beating the average prediction of $-19.514M by 17.03%. The company's net income was $-23.689M, missing the average estimation of $-35.741M by -33.72%. Apple's SG&A was $47.43M, beating the average forecast of $38.5M by 23.18%. Lastly, the company's EPS was $-0.0013, missing the average prediction of $-1.958 by -99.93%. In terms of the last quarterly report (Dec 2023), Exagen's revenue was $13.76M, beating the average analysts' forecast of $11.56M by 19.12%. The company's EBITDA was $-4.64M, missing the average prediction of $-5.34M by -13.11%. Exagen's net income was $-5.573M, missing the average estimation of $-7.858M by -29.08%. The company's SG&A was $12.22M, beating the average forecast of $10.54M by 15.93%. Lastly, the company's EPS was $-0.31, missing the average prediction of $-0.43 by -27.99%